Naïve B-cell receptor recognizing Human Papillomavirus type 6, 11, 16, and 18 L1 virus-like particles (BCR (HPV6/11/16/18 L1 VLP))

Naïve B-cell receptors (BCRs) recognizing Human Papillomavirus (HPV) type 6, 11, 16, and 18 L1 virus-like particles (VLPs) are the primary immunological targets for quadrivalent and nonavalent HPV vaccines (Schiller & Lowy, 2012, PubMed: 22430637). These receptors are membrane-bound immunoglobulins expressed on the surface of B-lymphocytes that have not yet encountered their cognate antigen. When the L1 VLPs—which structurally mimic the outer shell of the actual virus—bind to these specific BCRs, they initiate a cascade of signaling events leading to B-cell activation and the subsequent production of high-affinity neutralizing antibodies (FDA, 2020, Gardasil Package Insert). This process is crucial for establishing prophylactic immunity against HPV infections, which are the primary cause of cervical cancer, other anogenital cancers, and genital warts (WHO, 2022). By targeting these naïve BCRs, vaccines like Gardasil effectively prime the immune system to recognize and neutralize the virus upon future exposure. The interaction is highly specific to the L1 protein, the major capsid protein of HPV, and the resulting memory B-cell population provides long-lasting protection (Stanley, 2006, PubMed: 16566440). The success of this target interaction is measured by the induction of robust antibody titers that prevent the virus from entering host epithelial cells. Therapeutic challenges include ensuring broad population coverage and addressing the potential for type-replacement, although current evidence suggests the target remains highly effective for the specified HPV types.

Other names

HPV-specific B-cell receptorNaïve B-cell surface immunoglobulinAnti-HPV L1 BCR

The vaccine antigens (L1 virus-like particles) bind to and cross-link specific naïve B-cell receptors, triggering B-cell activation, clonal expansion, and differentiation into long-lived plasma cells and memory B-cells that produce neutralizing antibodies.